Benchmark Downgrades AbCellera Biologics to Hold
Portfolio Pulse from Benzinga Newsdesk
Benchmark analyst Robert Wasserman has downgraded AbCellera Biologics (NASDAQ:ABCL) from a Buy to a Hold rating.
August 20, 2024 | 11:40 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Benchmark analyst Robert Wasserman downgraded AbCellera Biologics from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100